Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate statistically meaningful outcomes versus autologous stem cell transplant (ASCT) for the frontline treatment of ...
Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback